Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable
Open Access
- 29 August 2006
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (6) , 691-698
- https://doi.org/10.1038/sj.bjc.6603327
Abstract
Prognostic and predictive factors in patients with metastatic renal cell carcinoma (MRCC) have been evaluated from untreated patients or patients on several different treatment approaches. The aim of this analysis was to define prognostic and predictive factors in patients treated uniformly with a low-dose outpatient cytokine combination. The relationship between patient-, tumour-, and treatment-related factors was analysed in 99 patients with MRCC. These features were first examined in univariate analyses, then a stepwise modelling approach based on Cox regression was used to form a multivariate model. Nuclear grade, metastasectomy – even incomplete – C-reactive protein and lactate dehydrogenase were identified as independent prognostic factors for survival. Patients assigned to three different risk groups had statistically significant survival differences (30, 22 and 6 months, respectively). A total of 43.4% had undergone metastasectomy, mostly incomplete. Risk group affiliation was correlated with response to treatment. Our findings strongly suggest the consideration of metastasectomy in the management of patients with metastatic renal cell cancer undergoing either immunotherapy or targeted treatment.Keywords
This publication has 29 references indexed in Scilit:
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and ErlotinibJournal of Clinical Oncology, 2005
- Prognostic Factors and Survival after Pulmonary Resection of Metastatic Renal Cell CarcinomaEuropean Urology, 2005
- Bevacizumab for Patients with Metastatic Renal CancerClinical Cancer Research, 2004
- Prognostic Factors for Survival of Patients with Stage IV Renal Cell CarcinomaClinical Cancer Research, 2004
- Thalidomide reduces serum C‐reactive protein and interleukin‐6 and induces response to IL‐2 in a fraction of metastatic renal cell cancer patients who failed IL‐2‐based therapyInternational Journal of Cancer, 2004
- Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal CancerJournal of Clinical Oncology, 2003
- Expression of the interleukin 6 receptor in primary renal cell carcinoma.Journal of Clinical Pathology, 1997
- Serum acute phase reactants and prognosis in renal cell carcinomaCancer, 1995
- Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancerClinical and Experimental Immunology, 1995